Pain Affecting Patents (Class 514/18.3)
-
Publication number: 20120083452Abstract: Topical anesthetic compositions include Szeto-Schiller peptides and a dermatologically acceptable carrier, and optionally a vasoconstrictor and tyrosine. A method of providing local analgesia to the skin involves applying to skin the topical anesthetic compositions.Type: ApplicationFiled: September 30, 2010Publication date: April 5, 2012Inventor: Nicholas V. Perricone
-
Publication number: 20120083453Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.Type: ApplicationFiled: January 24, 2011Publication date: April 5, 2012Applicant: BIOGEN IDEC MA INC.Inventor: Dinah W.Y. Sah
-
Publication number: 20120077747Abstract: A peptide-comprising extract derived from fish is described. Also disclosed is a process for obtaining a peptide-comprising extract derived from fish, as well as an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for example to prevent and/or treat an inflammatory and/or immune disease-related discomfort in a subject, are also described.Type: ApplicationFiled: October 23, 2009Publication date: March 29, 2012Applicant: Innovactiv Inc.Inventors: Raphael Anguenot, Martin Beaulieu, Jocelyn Bérubé, Sandrine Briate
-
Patent number: 8138155Abstract: A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula: B-L-TM where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B to TM.Type: GrantFiled: March 29, 2010Date of Patent: March 20, 2012Assignee: Manzanita Pharmaceuticals, Inc.Inventors: Robert R. Webb, Constance A. McKee
-
Publication number: 20120058951Abstract: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Inventors: Denise Barbut, Elliott Richelson
-
Publication number: 20120058950Abstract: Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and/or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and/or PACAP. Additionally, applicants have developed a transgenic non-human model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.Type: ApplicationFiled: November 11, 2011Publication date: March 8, 2012Applicants: University of Vermont and State Agricultural College, UNIVERSITY OF ROCHESTERInventors: Ronald W. Wood, Jay Reeder, Edward M. Schwarz, Edward M. Messing, Susan R. Schoen, Margaret A. Vizzard, Ian Dickerson
-
Publication number: 20120053126Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: ApplicationFiled: March 30, 2011Publication date: March 1, 2012Applicant: ALLERGAN, INC.Inventors: Catherine C. TURKEL, Mitchell F. Brin, Sheena K. Aurora, David W. Dodick
-
Publication number: 20120053127Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.Type: ApplicationFiled: June 13, 2011Publication date: March 1, 2012Applicant: ALLERGAN, INC.Inventor: Andrew BLUMENFELD
-
Publication number: 20120040911Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.Type: ApplicationFiled: December 18, 2009Publication date: February 16, 2012Inventor: ANDREW M. BLUMENFELD
-
Patent number: 8110549Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: March 8, 2011Date of Patent: February 7, 2012Assignee: University of Utah Research FoundationInventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
-
Patent number: 8106016Abstract: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.Type: GrantFiled: December 8, 2006Date of Patent: January 31, 2012Assignee: Shire LLCInventors: James Scott Moncrief, Suma Krishnan, Travis Mickle, Christopher Lauderback, Sanjib Bera, Sven Guenther, Wendy Hirschelman
-
Patent number: 8101573Abstract: The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of ?-Conotoxin MII that are selective for ?6-containing nAChRs as described herein.Type: GrantFiled: June 4, 2008Date of Patent: January 24, 2012Assignee: University of Utah Research FoundationInventor: J. Michael McIntosh
-
Publication number: 20120015886Abstract: The present invention relates to a method for producing a recombinant, spider toxin peptide and analgesic compositions containing said peptide. More specifically, the present invention relates to a method in which the gene for GsMTx4 is subcloned into a vector, so that it is linked to a secretion signal sequence of the alpha factor and under the control of methanol-inducible alcohol oxidase (AOX) promoter to construct a recombinant yeast expression plasmid. Yeast cells are transformed with this plasmid to produce the GsMTx4 peptide and analgesic compositions containing said peptide. The recombinant yeast expression system of the present invention affords a more stable method for producing GsMTx4 than its natural route. Thus the GsMTx4 peptide and its derivatives produced by the method of this invention can be used in the cure of related diseases such as heart failure as the peptide specifically inhibits mechanosensitive ion channels.Type: ApplicationFiled: October 19, 2010Publication date: January 19, 2012Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATIONInventors: UhTaek OH, Byung Moon Kim, Seung Pyo Park, Heung Sik Na
-
Publication number: 20120004180Abstract: The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumours.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Inventor: Andrej LIPKOWSKI
-
Publication number: 20120003290Abstract: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: July 5, 2011Publication date: January 5, 2012Inventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Publication number: 20120004175Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.Type: ApplicationFiled: March 28, 2008Publication date: January 5, 2012Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Zhiquan Zhang, Basil Rigas
-
Patent number: 8084429Abstract: Provided are compounds represented by: wherein R1 is a D-alanine, D-serine, D-threonine, D-methionine, D-leucine, D-asparagine or D-glutamine side chain and R2 is a phenylalanine or tryptophan side-chain, and compositions containing such compounds.Type: GrantFiled: August 7, 2003Date of Patent: December 27, 2011Inventors: Andrzej Lipkowski, Daniel Carr, Iwona Bonney, Dariusz Kosson, Aleksandra Misjecka-Kesik
-
Patent number: 8080519Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.Type: GrantFiled: January 15, 2010Date of Patent: December 20, 2011Assignee: ImmuPharma SA (France)Inventor: Robert H. Zimmer
-
Publication number: 20110294742Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.Type: ApplicationFiled: August 15, 2011Publication date: December 1, 2011Applicant: ALLERGAN, INC.Inventors: LANCE E. STEWARD, ESTER G. FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, SHENGWEN LI, KEI ROGER AOKI
-
Publication number: 20110288030Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: ApplicationFiled: August 1, 2011Publication date: November 24, 2011Applicant: Soricimed Biopharma Inc.Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Patent number: 8053476Abstract: The present invention concerns the use of compounds of the Formula (I) for treating different types of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain. The compounds show an antinociceptive profile and differ from classical analgesics like opioids and non-steroidal anti-inflammatory drugs (NSAIDs) and are useful as specific analgesics.Type: GrantFiled: August 21, 2006Date of Patent: November 8, 2011Assignee: UCB Pharma GmbHInventor: Norma Selve
-
Publication number: 20110263507Abstract: Neurotensin analogs selective for neurotensin receptor subtype 2 are described. These include hexapeptides (NT(8-13)) and pentapeptides (NT(9-13)) having a D-3,1-naphthyl-alanine, D-3,2-naphthyl-alanine, an alanine derivative such as cyclohexylalanine, or 1,2,3,4-tetrahydroisoquinoline at position 11. Methods of treating pain by administering these neurotensin analogs are also described.Type: ApplicationFiled: July 7, 2011Publication date: October 27, 2011Inventors: ELLIOTT RICHELSON, Daniel J. McCormick, Yuan-Ping Pang, Kenneth S. Phillips
-
Publication number: 20110251131Abstract: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.Type: ApplicationFiled: September 15, 2009Publication date: October 13, 2011Applicant: CONCERT PHARMACEUTICALS INC.Inventor: Craig E. Masse
-
Publication number: 20110245149Abstract: This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.Type: ApplicationFiled: May 19, 2011Publication date: October 6, 2011Applicant: NOUR HEART, INC.Inventors: Salwa A. ELGEBALY, Elliott SCHIFFMANN
-
Publication number: 20110236371Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLC?1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLC?1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.Type: ApplicationFiled: February 18, 2011Publication date: September 29, 2011Applicant: DUKE UNIVERSITYInventors: James O. McNamara, Xiao-Ping He, Yangzhong Huang, Bin Gu, Enhui Pan
-
Publication number: 20110237515Abstract: The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations.Type: ApplicationFiled: December 18, 2008Publication date: September 29, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS-, UNIVERSITE DE NICE SOPHIA ANTIPOLISInventors: Jean Mazella, Olivier Petrault, Marc Borsotto, Catherine Heurteaux, Catherine Widmann
-
Patent number: 8026217Abstract: Compositions and methods for protecting neural tissue (e.g., neurons) from anoxia and spreading depression (SD) involve inhibiting the cGMP-dependent protein kinase (PKG) pathway. It was discovered that the PKG pathway plays a crucial role in regulating SD and tolerance to anoxia in the central nervous system (CNS). Inhibition of the PKG pathway greatly reduces SD and increases tolerance to anoxia (i.e., hypoxia), while activation of the pathway exacerbates SD pathology. The compositions and methods can be used to treat any condition associated with SD or anoxia, including stroke, spinal cord injury, neurogenerative disease, dizziness, headaches, and migraines.Type: GrantFiled: October 3, 2008Date of Patent: September 27, 2011Assignee: Florida Atlantic UniversityInventors: Ken Dawson-Scully, R. Meldrum Robertson, Gary A. B. Armstrong, Marla Sokolowski
-
Patent number: 8026218Abstract: The present invention provides a novel chimeric compound comprising an agonist opioid receptor binding moiety at its N-terminus and an antagonist neurokinin-1 (NK1) receptor binding moiety at its C-terminus for producing analgesia, a pharmaceutical composition comprising the chimeric compound, a method of making the compound, and a method of treating pain using the novel chimeric compounds.Type: GrantFiled: June 8, 2007Date of Patent: September 27, 2011Assignee: The University of ArizonaInventors: Victor Hruby, Padma Nair, Takashi Yamamoto
-
Publication number: 20110230416Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).Type: ApplicationFiled: October 20, 2009Publication date: September 22, 2011Applicants: Vect-Horus, Centre National De La Recherche Scientifique, Universite De La MediterraneeInventors: Michel Khrestchatisky, Marion David, Yves Molion, Patrick Vlieghe
-
Patent number: 8017583Abstract: The disclosure herein relates to modified ?PKC inhibitory peptides, methods of generating such peptides, and method for using ?PKC inhibitory peptides for the treatment of pain.Type: GrantFiled: January 22, 2008Date of Patent: September 13, 2011Assignee: KAI Pharmaceuticals, Inc.Inventors: Derek MacLean, Qun Yin
-
Publication number: 20110206752Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.Type: ApplicationFiled: July 24, 2009Publication date: August 25, 2011Applicants: BCN PEPTIDES, S.A., DIVERDRUGS, S.L.Inventors: Cristina Carreno Serraima, Wim Van Den Nest, Antonio Ferrer Montiel, Maria Camprubi Robes, Jimena Fernandez Carneado, Berta Ponsati Obliols
-
Publication number: 20110207672Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.Type: ApplicationFiled: May 4, 2011Publication date: August 25, 2011Applicant: ELI LILLY AND COMPANYInventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
-
Publication number: 20110195909Abstract: An isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not Mr1A, Mr1B, Mar2, CMrV1A, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof.Type: ApplicationFiled: March 18, 2011Publication date: August 11, 2011Applicant: XENOME LTD.Inventors: Richard James Lewis, Paul Francis Alewood, Dianne Alewood, Elka Palant
-
Patent number: 7994133Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.Type: GrantFiled: May 24, 2010Date of Patent: August 9, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Daria Mochly-Rosen
-
Publication number: 20110189161Abstract: The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions.Type: ApplicationFiled: June 22, 2009Publication date: August 4, 2011Inventors: Kenneth Blum, Roger L. Waite, B. William Downs, William J. Heaney
-
Patent number: 7989421Abstract: The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.Type: GrantFiled: April 15, 2008Date of Patent: August 2, 2011Assignee: Neurotune AGInventors: Carlo Farina, Carla Ghelardini, Paola Petrillo
-
Patent number: 7985736Abstract: The present invention relates to compositions to treat CaV2 disorders. The invention also relates to methods treating CaV2 disorders. The invention further relates to kits for treating CaV2 disorders in a subject. The invention further relates to methods of identifying novel treatments for treating Cav2 disorders in a subject.Type: GrantFiled: December 14, 2005Date of Patent: July 26, 2011Assignee: The John Hopkins UniversityInventors: David T. Yue, Heather L. Agler
-
Patent number: 7968517Abstract: The present invention provides a method for preventing or treating opiate tolerance and dependence by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. The opiate tolerance and dependence can be caused by chronic morphine treatment and withdrawal. The blocking reagent can be an EphB receptor blocker such as EphB1-Fc and EphB2-Fc.Type: GrantFiled: October 31, 2008Date of Patent: June 28, 2011Assignee: Parker College of ChiropracticInventor: Xue-Jun Song
-
Publication number: 20110150769Abstract: The present application provides methods and compositions that can be used to treat persistent pain and to identify compounds that can be used for treating persistent pain. More specifically, agonists of members of the Mrgpr receptor family, particularly agonists of MrgprX1, can identified and screened for use in treating persistent pain, such as pain caused by inflammation or nerve injury.Type: ApplicationFiled: August 5, 2010Publication date: June 23, 2011Inventors: David J. Anderson, Xinzhong Dong, Qin Liu, Yun Guan
-
Publication number: 20110144001Abstract: The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) wherein {A}, {B}, {C}, R1-R6, m and n are as defined herein, obtainable from microorganism strain Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, a pharmaceutical composition comprising it, prepro-Labyrinthopeptin, pro-Labyrinthopeptin, and DNA coding for prepro-Labyrinthopeptin and pro-Labyrinthopeptin.Type: ApplicationFiled: September 30, 2010Publication date: June 16, 2011Applicant: SANOFI-AVENTISInventors: Mark BROENSTRUP, Hans GUEHRING, Holger HOFFMANN, Joachim WINK, Roderich SUESSMUTH, Timo SCHMIEDERER
-
Publication number: 20110129508Abstract: The present invention relates to the management of pain (nociceptive, neuropathic, inflammatory and disease related pains), using omega-conotoxins alone or in combination with neuronal excitation inhibitors (analgesics). The invention in particular provides methods, protocols, compositions and devices which treat, alleviate, prevent, diminish or otherwise ameliorate the sensation of pain.Type: ApplicationFiled: May 6, 2009Publication date: June 2, 2011Applicant: RELEVARE AUST. PTY LTDInventors: Ian Cooke, Colin Stanley Goodchild
-
Publication number: 20110124562Abstract: Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.Type: ApplicationFiled: March 11, 2009Publication date: May 26, 2011Inventor: Mark Y. Underwood
-
Publication number: 20110124571Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.Type: ApplicationFiled: April 7, 2009Publication date: May 26, 2011Applicant: INSTITUT PASTEURInventor: Catherine Rougeot
-
Publication number: 20110118189Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.Type: ApplicationFiled: April 24, 2009Publication date: May 19, 2011Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster
-
Publication number: 20110112035Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.Type: ApplicationFiled: July 7, 2009Publication date: May 12, 2011Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
-
Publication number: 20110105405Abstract: Use of PAM or functional fragments or derivatives thereof for the preparation of pharmaceutical compounds.Type: ApplicationFiled: October 4, 2010Publication date: May 5, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Martin MICHAELIS, Gerd GEISSLINGER, Klaus SCHOLICH, Irmgard TEGEDER
-
Publication number: 20110104301Abstract: Provided herein are methods of treating or preventing pain and/or inflammation in a subject comprising administering to the subject a transient receptor potential (TRP) ion channel inhibitor.Type: ApplicationFiled: May 29, 2009Publication date: May 5, 2011Inventors: Gerard Ahern, Jose A. Matta
-
Publication number: 20110104181Abstract: The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an ?2? subunit of a calcium channel.Type: ApplicationFiled: October 15, 2010Publication date: May 5, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Cagla EROGLU, Ben A. BARRES
-
Publication number: 20110091464Abstract: The present invention relates to a novel gene encoding a protein termed Coiled Coil Domain Containing 95 (CCDC95) or a peptide fragments thereof. The present invention also relates to the use of CCDC95 in Modulation of RGK small binding protein via altering concentration or sub-cellular localisation of RGK small binding protein with CCDC95 or a peptide fragments thereof.Type: ApplicationFiled: January 14, 2009Publication date: April 21, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Pascal Beguin, Walter Hunziker
-
Publication number: 20110082087Abstract: The present invention relates to a compound of formula (I) wherein X is hydrogen, R1, R1C(O), R1CO2, or a COX2 inhibitor, wherein R1 is C1-20 alkyl, aryl, arylalkyl, alkyloxy or arylalkyloxy; wherein Y is OR2, NHR3N(R3)2, or a COX inhibitor; wherein R2 is hydrogen or C1-20 alkyl and each R3 is independently hydrogen or a C1-4 alkyl; wherein T is OR4, NHR5N(R5)2, or a COX inhibitor wherein R4 is hydrogen or C1-20 alkyl and each R5 is independently hydrogen or a C1-4 alkyl; wherein Z is hydrogen, R6, R6C(O), R6CO2, or a COX2 inhibitor; wherein R6 is C1-20 alkyl, aryl, arylalkyl, alkyloxy or arylalkyloxy; with the proviso wherein when X and Z are hydrogen and T is OH, Y is not OH; for use in the prevention and/or treatment of pain wherein said compound is provided for systemic administration.Type: ApplicationFiled: April 1, 2009Publication date: April 7, 2011Applicant: Edificio ICATInventors: Marta Maria Batista Ribeiro, Miguel Augusto Rico Botas Castanho, Christophe Francois Aime Roca, Helena Margarida Moreira de Oliveira Vieira, Jose Manuel Bernardo de Sousa, Marta Isabel Heitor Cerejo, Patricia Ramalhete Mendes da Silva Calado, Sukalyan Chatterjee, Eduard Bardaji Rodriguez, Montserrat Heras Corominas, Isaura Ferreira Tavares, Marta Sofia Carvalho Teixeira Pinto, Ana Dulce Ascensao Correia, Manuel Nuno de Sousa Simoes de Mel